MK-4305 (Suvorexant)

Catalog No.: A11500

OX receptor antagonist

MK-4305 (Suvorexant)

MK-4305 (Suvorexant) Chemical Structure

CAS NO. 1030377-33-3

Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.

Availability: In stock

Package Price Qty
5 mg
$90.00
10 mg
$160.00
25 mg
$350.00
50 mg
$600.00
10mM * 1mL in DMSO
$140.00
Custom Size Get quote

Free Overnight Delivery on orders over $500

Next day delivery by 10:00 a.m. Order now.

Warning Products are for laboratory research use only. Not for human use. We do not sell to patients.
  • Zhang B, .et al. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex, Neurobiol Dis, 2019, Oct 9;134:104615 PMID: 31605778
  • Obara K, .et al. Assessment of Inhibitory Effects of Hypnotics on Acetylcholine-Induced Contractions in Isolated Rat Urinary Bladder Smooth Muscle, Biol Pharm Bull, 2019, 42(2):280-288 PMID: 30713259
  • James B Jaggard, .et al. Hypocretin underlies the evolution of sleep loss in the Mexican cavefish, eLife, 2018, 7: e32637 PMID: 29405117
  • Skillman B, .et al. Quantification of suvorexant in blood using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, 2018, Aug 1;1091:87-95 PMID: 29859493
  • Clark L, .et al. On the use of Pichia pastoris for isotopic labeling of human GPCRs for NMR studies, J Biomol NMR, 2018, Aug;71(4):203-211 PMID: 30121871
  • Sullinger S, .et al. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS), J Anal Toxicol, 2017, Apr 1;41(3):224-229 PMID: 28035034
  • Carson M, .et al. Quantification of suvorexant in urine using gas chromatography/mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, 2017, Jan 1;1040:289-294 PMID: 27825624

Biological Activity

Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.
Targets
OX2 receptor OX1 receptor
0.35 nM(Ki)0.55 nM(Ki)
In vitro DMSO 10 mg/mL (22.17 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 22.18 mL 110.88 mL 221.77 mL
0.5 mM 4.44 mL 22.18 mL 44.35 mL
1 mM 2.22 mL 11.09 mL 22.18 mL
5 mM 0.44 mL 2.22 mL 4.44 mL

*The above data is based on the productmolecular weight 450.92. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Catalog Num A11500
Actions Antagonist
M. Wt 450.92
Formula C23H23ClN6O2
Solubility DMSO
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1030377-33-3
Synonyms MK4305, MK 4305
SMILES C[[email protected]@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl

Product Tags

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

Product Questions

Product Questions

No Questions
Keywords:buy MK-4305 (Suvorexant) | MK-4305 (Suvorexant) Supplier | purchase | cost | manufacturer | order | distributor | buy 1030377-33-3| 1030377-33-3 Supplier | purchase 1030377-33-3 | 1030377-33-3 cost | 1030377-33-3 manufacturer | order 1030377-33-3 | 1030377-33-3 distributor
Rewards